Temporal-Enhanced Interpretable Multi-Modal Prognosis and Risk Stratification Framework for Diabetic Retinopathy (TIMM-ProRS)
Susmita Kar, A S M Ahsanul Sarkar Akib, Abdul Hasib, Samin Yaser, Anas Bin Azim
TL;DR
Diabetic retinopathy poses rising global vision-loss risk and diagnostic ambiguity, especially in underserved regions. The paper introduces TIMM-ProRS, a multi-modal framework that fuses CNN-derived local retinal features, ViT-based global context, and GNN-modeled temporal biomarkers to produce DR grading and 5-year progression risk, augmented with interpretability and uncertainty quantification. The approach achieves state-of-the-art results across diverse datasets (APTOS 2019, Messidor-2, EyePACS, Messidor-1, RFMiD), including $97.8%$ accuracy and a $0.89$ C-index for progression risk, while providing saliency maps with clinician-aligned explanations and robust generalization. This work advances telemedicine readiness by delivering early, interpretable prognosis and scalable risk stratification, with future plans for real-world longitudinal validation and expanded biomarker integration (e.g., VEGF) to further personalize care.
Abstract
Diabetic retinopathy (DR), affecting millions globally with projections indicating a significant rise, poses a severe blindness risk and strains healthcare systems. Diagnostic complexity arises from visual symptom overlap with conditions like age-related macular degeneration and hypertensive retinopathy, exacerbated by high misdiagnosis rates in underserved regions. This study introduces TIMM-ProRS, a novel deep learning framework integrating Vision Transformer (ViT), Convolutional Neural Network (CNN), and Graph Neural Network (GNN) with multi-modal fusion. TIMM-ProRS uniquely leverages both retinal images and temporal biomarkers (HbA1c, retinal thickness) to capture multi-modal and temporal dynamics. Evaluated comprehensively across diverse datasets including APTOS 2019 (trained), Messidor-2, RFMiD, EyePACS, and Messidor-1 (validated), the model achieves 97.8\% accuracy and an F1-score of 0.96, demonstrating state-of-the-art performance and outperforming existing methods like RSG-Net and DeepDR. This approach enables early, precise, and interpretable diagnosis, supporting scalable telemedical management and enhancing global eye health sustainability.
